Back to Journals » Clinical Ophthalmology » Volume 15

Comparing Healthcare Resource Utilization and Costs for Patients with Normal Tension Glaucoma Across Levels of Severity: A Retrospective Cohort Study

Authors Beal B, Shih V, Campbell J, Veenstra D, Devine B

Received 20 November 2020

Accepted for publication 26 January 2021

Published 9 February 2021 Volume 2021:15 Pages 453—460

DOI https://doi.org/10.2147/OPTH.S284474

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser


Brennan Beal,1 Vanessa Shih,2 Joanna Campbell,2 David Veenstra,1 Beth Devine1

1The Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA; 2Healthcare Economics and Outcomes Research, AbbVie, Chicago, IL, USA

Correspondence: Brennan Beal
The Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington, Suite H-375, Box 35760, 1959 NE Pacific Street, Seattle, WA, 98195-7630, USA
Tel +1 704 742 0288
Fax +1 206-543-3835
Email brennanbeal@gmail.com

Purpose: To estimate the healthcare resource utilization (HCRU) and costs for patients with normal tension glaucoma (NTG) as well as their payers across various levels of disease severity.
Patients and Methods: Our study was a retrospective cohort study of 6330 US NTG patients. Patients were enrolled if they were 40 years or older and had two or more qualifying NTG diagnoses within the enrollment period, October 1st, 2015 to December 31st, 2017. Our analysis was carried out for two cohorts – those with unilateral disease and those with bilateral disease. Baseline demographic and clinical characteristics were assessed for a 12-month pre-index period. The follow up period was 12-months post-index. We employed generalized linear models to model HCRU and costs.
Results: Patients with severe, bilateral disease, filled more than two additional prescriptions annually (2.5, p< 0.001, 95% CI [2.0, 3.1]) when compared to their mild counterparts and accounted for 111 (p< 0.001, 95% CI [83.5, 139.1]) extra days of supply of glaucoma medications. These patients face an adjusted $187 (p< 0.001, 95% CI [145, 229]) more out-of-pocket (OOP), and payers an additional $598 (p< 0.001, 95% CI [$370, $826]), than their counterparts with a mild diagnosis on an annual basis. Total annual payer costs, on average (SD) for those with severe bilateral NTG were $1175 ($2222).
Conclusion: Our results suggest that patient and payer burden is significantly greater for those with severe disease compared to those with mild NTG. The excess burden is attributed to additional HCRU and the associated financial burden. Payers experienced a much larger financial burden from patients with severe disease compared to those with mild NTG. Approximately half of the cost differences can be attributed to additional prescription use.

Keywords: healthcare resource utilization, normal tension glaucoma, low tension glaucoma, healthcare costs

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]